

PERSONAL INFORMATION



Aldo Pietro Maggioni

 Piazzale Biancamano, 2, 20121, Milan, Italy

 +39 055 5101205  +39 335 258338

 maggioni@anmco.it

ORCID ID <https://orcid.org/0000-0003-2764-6779>

Sex M | Date of birth 25/02/1949 | Nationality Italian

**JOB APPLIED FOR POSITION
PREFERRED JOB STUDIES
APPLIED FOR**

Director of Research Center of Italian Association of Hospital Cardiologists (ANMCO), Florence, Italy

WORK EXPERIENCE

1996 to date

Director of Research Center of Italian Association of Hospital Cardiologists (ANMCO), Florence, Italy

Fondazione per il Tuo cuore, Via La Marmora 36, 50121 Florence, Italy

- Planning, organizing and conducting clinical trials in cardiovascular care. Analysis and interpretation of their results.

2010 to date

Business or sector Research Center, no profit research foundation

Scientific Coordinator of the Euroobservational Research Programme (ESC)

European Society of Cardiology (ESC), Sophia Antipolis cedex, France

- Planning, organizing and conducting observational research in cardiovascular disease. Analysis and interpretation of their results.

1994 to 1996

Co-director of the department of cardiovascular research

IRCCS Mario Negri Institute, Via G. La Masa 19, 20156 Milano, Italy

- Planning, organizing and conducting observational research in cardiovascular care. Analysis and interpretation of their results.

1992 to 1994

Business or sector Department of Cardiovascular Research. No profit research institute

Vice Head

Division of Internal Medicine and Cardiology, General Hospital "Fatebenefratelli", Milano, Italy

- Periodically responsible for wards, coronary unit and electrophysiology lab

1988 to 1992

Business or sector Hospital

Vice Head

Division of Internal Medicine and Cardiology, General Hospital "G. Fornaroli", Magenta, Italy

- Periodically responsible for wards, coronary unit and electrophysiology lab

1978 to 1987

Business or sector Hospital

Clinical Cardiologist

Division of Cardiology, General Hospital "G. Fornaroli", Magenta, Italy

- Periodically responsible for wards, coronary unit and electrophysiology lab

1975 to 1978

Business or sector Hospital

Clinical Cardiologist

Emergency Room, Ospedale C. Cantù, Abbiategrasso

- Assistant in the emergency room of a public hospital with an area of approximately 300,000 inhabitants

Business or sector Hospital

AWARDS

- 2016 Gold Medal of the Italian Association of Hospital Cardiologists (ANMCO)
- 2017 GIMBE Evidence Award
- 2017 Commander of the Italian Republic
- 2019 Gold Medal of the Heart Failure Association of the European Society of Cardiology (ESC)

EDUCATION AND TRAINING

- 1975 to 1978 **Postgraduate degree in cardiovascular diseases** 70/70 cum laude
University of Padova
 - Postgraduate school in cardiovascular diseases
- 1968 to 1974 **Medical Degree** 110/110 cum laude
University of Milan
 - Postgraduate school in cardiovascular diseases
- 1963 to 1968 **High school diploma (classical studies)** 7/10
Liceo Classico Berchet, Milano

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
Replace with language	Enter level	Enter level	Enter level	Enter level	Enter level
Replace with name of language certificate. Enter level if known.					

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Communication skills

Thirty-year tradition of group occupational activity of hospital care and clinical research.
▪ Twenty years multinational collaboration on planning, organizing and conducting clinical trials in cardiovascular, renal and metabolic care.

Organisational / managerial skills

Nearly 20 years of management experience in the field of no profit research with national and International collaborations

Computer skills

Use of writing programs: Word, Excel e PowerPoint
▪ good command of Microsoft Office™ tools

Other skills

▪ Writing

Driving licence

▪ Italian driving licence type B

ANNEXES

- 1 – Scientific and Academic experience
- 2 – Experience in Regulatory activities
- 3 – Participation in Clinical Studies
- 4 – Publications last three years

Milan, July 8, 2020

Aldo P. Maggioni



I allow the processing of personal data contained in my curriculum vitae based on Article 13 of Legislative Decree 196/2003 and Article 13 of EU Regulation 2016/679 (GDPR) for the same purposes of ECM accreditation and all the procedures referable to it.

ANNEXE 1. Scientific and Academic experience

1996 to 2007: Associate Editor of the following Journal: Evidence-Based Cardiovascular Medicine.

1996 to date: Associate Editor of the following Journal: Italian Journal of Cardiology (now Journal of Cardiovascular Medicine)

2000 to date: Editorial Board of: European Heart Journal; Cardiovascular Drugs and Therapy; European Heart Journal of Heart Failure

2002 to 2009: National Coordinator of the Euro Heart Surveys

2005 to 2009: Contract Professor of Methodology of Clinical Research at the University of Bologna

2007 to date: Contract Professor of the Master on Epidemiology and Methodology of Clinical Research at the Univ. of Ferrara

2008 to 2010: Member of the Board of the Association on Heart Failure of the European Society of Cardiology

2010 to date: General Secretary of the Board of the Association on Heart Failure of the European Society of Cardiology

2008 to 2013: Editorial Board of: Circulation Cardiovascular Quality and Outcomes; BMJ Clinical cases

2009 to date: Scientific Coordinator of the EURObservational Research Program of the European Society of Cardiology

2010 to date: Guest Editor of Circulation

2015: included in the list of highly cited researchers over the last 11 years (2003-2013) by Thomson Reuters

2016: included in the list of highly cited researchers for year 2015 by Thomson Reuters

2016 to date: Associate Editor of the International Journal of Cardiology

ANNEXE 2. Experience in Regulatory activities

2002 to 2010: Member of the EMEA Efficacy Working Party (EWP) Therapeutic Subgroup on Cardiovascular/Pulmonary issues (CVS)

2006 to 2009: Consultant of the AIFA (Italian Agency of Drugs) for: Scientific Advices, Centralized Procedures, Mutual Recognition Procedures, Drug approvals, Post marketing pharmaco-vigilance, Outcome studies for the evaluation of the effectiveness of potentially innovative drugs

2019: included in the register of experts, collaborators and researchers of AGENAS

ANNEXE 3. Participation in Clinical Studies

The main activities in the last 35 years have been focused on the conduction of clinical trials and surveys/registries in the field of:

- *Cardiology*: acute coronary syndromes, cardiovascular prevention, arrhythmias, acute and chronic heart failure
- *Cerebrovascular diseases*
- *Renal diseases*
- *Endocrinology*: diabetes, obesity

The list of trials and the description of the responsibility in their conduction is reported below. The active participation in these large number of epidemiological and controlled studies provided a deep knowledge and expertise in clinical trial methodology.

Arrhythmias

ADEG (member of the Steering Committee)

GISSI-AF (member of the Steering Committee)

ACTIVE (member of the Clinical Events Evaluation Committee)

ARISTOTLE (member of the Safety and Data Monitoring Board)

SYNCRIA (member of the Safety and Data Monitoring Board)

OPERA (member of the Clinical Events Evaluation Committee)

Myocardial infarction

GISSI-1 (member of the Clinical Events Evaluation Committee)

GISSI-2 (member of the Coordinating Center)

GISSI-3 (member of the Coordinating Center)

GISSI-EFRIM (member of the Steering Committee)

GISSI Nursing (member of the Steering Committee)

GISSI-Prognosis (member of the Steering Committee)

ISIS-3 (member of the Steering Committee)

ISIS-4 (member of the Steering Committee)

ECLA-3 (member of the Scientific Committee)

CORE (member of the Steering Committee)

OAT (member of the Steering Committee)

LATIN (member of the Executive Committee and Study Coordinator)

MISTRAL (member of the Executive Committee and Study Coordinator)

ASSENT-2 (member of the Safety and Data Monitoring Board)

ASSENT-3 (member of the Safety and Data Monitoring Board)

ASSENT-3 Plus (member of the Safety and Data Monitoring Board)

ASSENT-4 (member of the Safety and Data Monitoring Board)

VALIANT (member of the Executive and of the Steering Committee)

BEAUTIFUL (member of the Steering Committee, as National Leader)

BLITZ 1 (member of the Executive Committee)

APPRAISE 2 (member of the Safety and Data Monitoring Board)

PARADISE (member of the Executive and of the Steering Committee)

CHIARA MIA (chairman of the Data Monitoring Committee)

Unstable angina/NSTEMI

OASIS-2 (member of the Steering Committee)
CURE (member of the Steering Committee)
EMAI (member of the Steering Committee)
CURRENT (member of the Steering Committee)
APPRAISE 2 (member of the Safety and Data Monitoring Board)
BLITZ 2 (member of the Executive Committee)

Cardiovascular Prevention

GISSI-Prevenzione (member of the Coordinating Center)
PEACE (member of the Steering and of the Clinical Events Evaluation Committee)
RUTH (member of the Clinical Events Evaluation Committee)
NAVIGATOR (member of the Safety and Data Monitoring Board)
ONTARGET/TRANSCEND (member of the Steering Committee, member of the Clinical Events Evaluation Committee)
SIGNIFY (member of the Safety and Data Monitoring Board)
Dal-OUTCOME (National Coordinator)
CARDYOSIS (member of the Steering Committee)
ISCHEMIA (member of the Steering Committee)
REVEAL-HPS3 (member of the Steering Committee)
COMPASS (member of the Steering Committee)
COLCOT (member of the Steering Committee)
DalGene (member of the Steering Committee)

Heart Failure

RESOLVD Pilot Study (co-chairman of the study)
SPICE Study (member of the Steering Committee)
IN-CHF Registry (member of the Steering Committee and Study Coordinator)
SEOSI Study (member of the Steering Committee)
Val-HeFT Trial (deputy member of the Steering Committee)
BRING-UP Trial (member of the Steering Committee and Study Coordinator)
CHARM Trial (member of the Steering Committee)
OVERTURE (member of the Steering Committee)
GISSI-HF (member of the Steering Committee)
EVEREST (member of the Steering/Executive Committee)
RED-HF (member of the Steering/Executive Committee)
RENO DEFEND (member of the Steering/Executive Committee)
ATMOSPHERE (National Coordinator)
ASTRONAUT (co-chairman of the Steering/Executive Committee)
COMPOSE (member of the Steering Committee)
ARTS (chairman of the Safety and Data Monitoring Board)
ESC HF-Pilot (chairman of the Steering/Executive Committee)
ESC HF Long-Term Registry (chairman of the Steering/Executive Committee)
RESHAPE-HF (member of the Steering/Executive Committee)
TRUE-HF (member of the Steering/Executive Committee)
SOCRATES (member of the Steering/Executive Committee)
PARAGON (member of the Steering/Executive Committee)
ARTS-2 (member of the Steering/Executive Committee)
RELAX-AHF-EU (chairman of the Steering/Executive Committee)
ARIADNE (chairman of the Steering/Executive Committee)
PURE HF (member of the Safety and Data Monitoring Board)
FINEART-HF (chairman of the Data Monitoring Committee)

Pulmonary hypertension

COMPASS II (member of the Safety and Data Monitoring Board)

Diabetes/obesity

ORIGIN (member of the Steering Committee)
SCOUT (member of the Steering/Executive Committee)
TIDE (member of the Steering Committee)
ELIXA (member of the Executive and of the Steering Committee)
EXSCEL (member of the Executive and of the Steering Committee)
FIDELIO-CKD (chairman of the Data Monitoring Committee)
FIGARO-CKD (chairman of the Data Monitoring Committee)
DYDA (member of the Steering Committee)

Renal diseases

ARI (member of the Steering Committee)
ALTITUDE (National Coordinator)
EMPA-KIDNEY (member of the Steering Committee)

Stroke

MAST (member of the Clinical Events Evaluation Committee)

ANNEXE 4. Publications (2019-2017)

Year 2019

1. Maggioni AP, Dondi L, Andreotti F, Pedrini A, Calabria S, Ronconi G, Piccinni C, Martini N. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. *Am Heart J*. 2019 Nov 9;220:12-19. doi: 10.1016/j.ahj.2019.10.017. [Epub ahead of print]
2. Comaschi M, Di Lenarda A, Medea G, Aglialoro A, Cucinotta D, Gulizia M, Vespasiani G, Zuin G, Nicolucci A, Spandonaro F, Maggioni AP. INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study. *Diabetes Ther*. 2019 Nov 22. doi: 10.1007/s13300-019-00731-x. [Epub ahead of print]
3. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights from the EXSCEL Trial. *Diabetes Care*. 2019 Nov 22. pii: dc191065. doi: 10.2337/dc19-1065. [Epub ahead of print]
4. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. *Circulation*. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491. [Epub ahead of print]
5. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med*. 2019 Nov 16. doi: 10.1056/NEJMoa1912388. [Epub ahead of print]
6. Savonitto S, De Servi S, Maggioni AP, Cesana BM. [Early interruption of a clinical trial: rationale and interpretation]. *G Ital Cardiol (Rome)* 2019;20(11):619-626.
7. Balabanski T, Brugada J, Arbelo E, Laroche C, Maggioni A, Blomström-Lundqvist C, Kautzner J, Tavazzi L, Tritto M, Kulakowski P, Kalejs O, Forster T, Villalobos FS, Dagues N; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators Group. Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. *Europace*. 2019 Aug 13. pii: euz216. doi: 10.1093/europace/euz216. [Epub ahead of print]
8. Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, González-Costello J, López-Fernández S, García-Pinilla JM, Almenar-Bonet L, de Juan-Bagudá J, Roig-Minguell E, Bayés-Genís A, Sanz-Julve M, Lambert-Rodríguez JL, Lara-Padrón A, Pérez-Ruiz JM, Fernández-Vivancos Marquina C, de la Fuente-Galán L, Varela-Román A, Torres-Calvo F, Andrés-Novales J, Escudero-González A, Pascual-Figal DA, Ridocci-Soriano F, Sahuquillo-Martínez A, Bierge-Valero D, Epelde-Gonzalo F, Gallego-Page JC, Dalmau González-Gallarza R, Bover-Freire R, Quiles-Granado J, Maggioni AP, Lund LH, Muñoz J, Delgado-Jiménez J. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. *Rev Esp Cardiol (Engl Ed)*. 2019 Oct 28. pii: S1885-5857(19)30285-3. doi: 10.1016/j.rec.2019.05.015. [Epub ahead of print] English, Spanish.
9. Polewczyk A, Rinaldi CA, Sohal M, Golzio PG, Claridge S, Cano O, Laroche C, Kennergren C, Deharo JC, Kutarski A, Butter C, Blomström-Lundqvist C, Romano SL, Maggioni AP, Auricchio A, Diemberger I, Pisano ECL, Rossillo A, Kuck KH, Forster T, Bongiorni MG; ELECTRa investigators group. Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTROLled ELECTRa registry: is female sex a predictor of complications? *Europace*. 2019 Oct 30. pii: euz277. doi: 10.1093/europace/euz277. [Epub ahead of print]
10. Savonitto S, De Servi S, Maggioni AP, Cesana BM. Interruzione anticipata delle sperimentazioni cliniche: razionale e interpretazione. *G Ital Cardiol (Rome)* 2019;20(11):619-626.
11. Nof E, Bongiorni MG, Auricchio A, Butter C, Dagues N, Deharo JC, Rinaldi CA, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Milman A, Beinart R, Bogdan S, Mortsell D, Calvi V, Desiron Q, Mansourati J, Lundqvist CB, Glikson M. Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. *Europace*. 2019 Oct 18. pii: euz269. doi: 10.1093/europace/euz269. [Epub ahead of print]
12. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. *Eur J Prev Cardiol*. 2019 Oct 15:2047487319882154. doi: 10.1177/2047487319882154. [Epub ahead of print]
13. Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L, Kerneis M, Valgimigli M, Gale CP; CICD investigators group. Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. *Eur Heart J Qual Care Clin Outcomes*. 2019 Oct 11. pii: qcz057. doi: 10.1093/ehjqcco/qcz057. [Epub ahead of print]
14. Lettino M, Maggioni AP. [Conclusions]. *G Ital Cardiol (Rome)*. 2019 Oct;20(10 Suppl. 2):24-25.
15. Lettino M, Maggioni AP. [Introduction]. *G Ital Cardiol (Rome)*. 2019 Oct;20(10 Suppl. 2):3.
16. Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. *J Am Coll Cardiol* 2019;74:1519-1528

17. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. *Lancet*. 2019 Sep 17. pii: S0140-6736(19)32131-2. doi: 10.1016/S0140-6736(19)32131-2. **[ACKNOWLEDGEMENT]**
18. Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Rydén L, Verhamme P, Widimsky P, Zhu J, Yusuf S; COMPASS investigators. Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis. *Circulation* 2019;140:1451-1459.
19. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, De Bonis M, Tribouilloy C, Evangelista A, Bogachev-Prokophiev A, Apor A, Ince H, Laroche C, Popescu BA, Piérard L, Haude M, Hindricks G, Ruschitzka F, Windecker S, Bax JJ, Maggioni A, Vahanian A; EORP VHD II Investigators. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. *Circulation*. 2019 Sep 12. doi: 10.1161/CIRCULATIONAHA.119.041080. **[Epub ahead of print]**
20. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O, Maggioni AP, Lancellotti P. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. *Eur Heart J*. 2019 Oct 14;40(39):3222-3232.
21. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. *N Engl J Med*. 2019 Sep 1. doi: 10.1056/NEJMoa1908655. **[Epub ahead of print]**
22. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. *Eur Heart J* 2019; 40:2745–2759.
23. Andreini D, Magnoni M, Conte E, Masson S, Mushtaq S, Berti S, Canestrari M, Casolo G, Gabrielli D, Latini R, Marraccini P, Moccetti T, Modena MG, Pontone G, Gorini M, Maggioni AP, Maseri A; CAPIRE Investigators. Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. *JACC Cardiovasc Imaging*. 2019 Aug 8. pii: S1936-878X(19)30611-4. doi: 10.1016/j.jcmg.2019.06.019. **[Epub ahead of print]**
24. Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP; DYDA 2 Investigators. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. *Cardiovasc Drugs Ther*. 2019 Aug 15. doi: 10.1007/s10557-019-06898-6. **[Epub ahead of print]**
25. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, Pokushalov E, Maggioni AP, Laroche C, Anselmino M, Beinart R, Traykov V, Lundqvist CB; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators. Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. *Pacing Clin Electrophysiol*. 2019 Oct;42(10):1365-1373.
26. Maggioni AP, Andreotti F. Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort? *Eur Heart J*. 2019 Aug 1. pii: ehz523. doi: 10.1093/eurheartj/ehz523.
27. Hallén J, Maggioni AP, Lopez-de-Sa E, Turazza FM, Witte K, Erdmann E, Dahlström U, Ertl G, Nielsen OW, Lopez Sendon J, Holbro T, Chen CW, Gimpelewicz C, Cowie MR. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. *Eur J Heart Fail*. 2019 Jul 29. doi: 10.1002/ejhf.1574.
28. Maggioni AP. Omega-3 Fatty Acids and Heart Failure: Evidence and Still Open Questions. *JACC Heart Fail* 2019;7:662-663.
29. Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *JACC Heart Fail*. 2019 Oct;7(10):862-874.
30. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S. Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. *Circulation* 2019;140:529-537.
31. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogossova N, Dans AL, Lanan F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusuf K, Metsarinné KP, Fox KAA, Yusuf S; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. *Gastroenterology* 2019;157:682-691.e2.
32. Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolta L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; HF LT Registry Investigators group. Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world. *Eur J Heart Fail*. 2019 May 27. doi: 10.1002/ejhf.1532. **[Epub ahead of print]**
33. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH; ESC-EORP HFA Heart Failure Long-Term Registry Investigators. Acute

- heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail.* 2019 May 24. doi: 10.1002/ehf.1492. [Epub ahead of print]
34. Maggioni AP. Appropriate prescriptions mean better outcomes: how can we improve ourselves? *Eur J Heart Fail* 2019; 21:930-931.
 35. Di Cori A, Auricchio A, Regoli F, Blomström-Lundqvist C, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Rinaldi CA, Dovellini EV, Golzio PG, Thøgersen AM, Bongiorno MG; ESC-EHRA ELECTRa Investigators. Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry. *Europace* 2019;21:1096-1105. doi: 10.1093/europace/euz062.
 36. Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A; TOSCA.IT investigators. Cardiovascular effects of pioglitazone or sulphonylureas according to pretreatment risk: moving towards personalized care. *J Clin Endocrinol Metab.* 2019 Aug 1;104(8):3296-3302.
 37. Zeymer U, Ludman P, Danchin N, Kala P, Maggioni AP, Weidinger F. THE ESC ACCA EAPCI EORP Acute Coronary Syndrome ST elevation myocardial infarction (ACS STEMI) REGISTRY. *Eur Heart J Qual Care Clin Outcomes.* 2019 Jul 30. pii: qcz042. doi: 10.1093/ehjqcco/qcz042.
 38. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfeld J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko A, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusuf S, Yusuf S; COMPASS investigators. Pantoprazole to Prevents Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. *Gastroenterology* 2019;157:403-412.e5.
 39. De Backer G, Jankowski P, Kotseva K, Mirrahimov E, Reiner Ž, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D; EUROASPIRE V collaborators; Writing Committee; Scientific Steering/ Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. *Atherosclerosis* 2019;285:135-146.
 40. Arca M, Canonico PL, Colivicchi F, Favaretti C, Perrone Filardi P, Maggioni AP. L'importanza degli inibitori della PCSK9 nella prevenzione secondaria di eventi cardiovascolari in pazienti con malattia aterosclerotica: un'analisi GRADE dello studio Fourier per l'evolocumab. In: Clinico Economics. Anno 2019/Supplemento 1. SAVE, Milano.
 41. Habib G, Lancellotti P, Erba PA, Sadeghpour A, Meshaal M, Sambola A, Furnaz S, Citro R, Ternacle J, Donal E, Cosyns B, Popescu B, lung B, Prendergast B, Laroche C, Tornos P, Pazdernik M, Maggioni A, Gale CP; EURO-ENDO Investigators. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. *Eur Heart J Qual Care Clin Outcomes* 2019;5:202-207.
 42. Piccinni C, Calabria S, Ronconi G, Dondi L, Pedrini A, Esposito I, Marangolo M, Maggioni AP, Martini N. [Facts and figures of clinical pathways in Italy: results from the PDTA Net project.] *Recenti Prog Med* 2019;110:188-194.
 43. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). *Eur Heart J.* 2019 Mar 25. pii: ehz136. doi: 10.1093/eurheartj/ehz136. [Epub ahead of print]
 44. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. *Europace* 2019;21:1013-1022.
 45. SPS I supplementi di Politiche sanitarie. Concept paper sul Progetto inibitori di PCSK9: accesso e sostenibilità. Pensiero Scientifico Editore. SPS n. 1, 2019.
 46. Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Alexander KP, Senior R, Boden WE, Stone GW, Goodman SG, Lopes RD, Lopez-Sendon J, White HD, Maggioni AP, Shaw LJ, Min JK, Picard MH, Berman DS, Chaitman BR, Mark DB, Spertus JA, Cyr DD, Bhargava B, Ruzyllo W, Wander GS, Chernyavskiy AM, Rosenberg YD, Maron DJ; ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. *JAMA Cardiol* 2019;4:273-286.
 47. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J, Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S, Mellbin L, Milicic D, Mirrahimov E, Oganov R, Pogosova N, Reiner Z, Störk S, Tokgözoğlu L, Tsioufis C, Vulic D, Wood D; EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol* 2019;26:824-835.
 48. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;393:407-415.
 49. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowicz SD, Cook Bruns N, Yusuf S, Eikelboom JW. Stroke Outcomes in COMPASS Trial. *Circulation* 2019;139:1134-1145.
 50. Ozierański K, Balsam P, Kaplon-Cieślicka A, Tymieńska A, Kowalik R, Grabowski M, Peller M, Wancerz A, Marchel M, Crespo-Leiro MG, Maggioni AP, Drożdż J, Filipiak KJ, Opolski G. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. *Cardiovasc Drugs Ther* 2019;33:77-86.

51. Balsam P, Ozierański K, Kapłon-Cieślicka A, Borodzicz S, Tymieńska A, Peller M, Marchel M, Crespo-Leiro MG, Maggioni AP, Drożdż J, Opolski G, Grabowski M. Differences in clinical characteristics and one-year outcomes of hospitalized heart failure patients in succeeding European Society of Cardiology-Heart Failure Registries - Pilot and Long-Term. **Pol Arch Intern Med** 2019;**129**:106-116.
52. Antonini L, Mollica C, Aspromonte N, Pasceri V, Auriti A, Gonzini L, Maggioni P, Colivicchi F. A simple prognostic index in acute heart failure. **Minerva Cardioangiol** 2019;**67**:73-78.
53. Paolillo S, Veglia F, Salvioni E, Corrà U, Piepoli M, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Senni M, Bonomi A, Scrutinio D, Raimondo R, Emdin M, Magri D, Parati G, Re F, Cicoira M, Minà C, Correale M, Frigerio M, Bussotti M, Battaia E, Guazzi M, Badagliacca R, Di Lenarda A, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Clemenza F, Binno S, Lombardi C, Filardi PP, Agostoni P; MECKI Score Research Group (see Appendix). Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. **Eur J Heart Fail** 2019;**21**:208-217.
54. Stabile G, Trines SA, Arbelo E, Dagres N, Brugada J, Kautzner J, Pokushalov E, Maggioni AP, Laroche C, Anselmino M, Beinart R, Traykov V, Blomström Lundqvist C; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators. Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESC-EHRA atrial fibrillation ablation long term registry. **Pacing Clin Electrophysiol** 2019;**42**:313-320.
55. Maggioni AP. Where are we with the Euroobservational Research Programme in 2018? **Dialogues Cardiovasc Med.** 2019;**24**(#1):76-80
56. Segreti L, Rinaldi CA, Claridge S, Svendsen JH, Blomstrom-Lundqvist C, Auricchio A, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Kempa M, Magnani A, Casteigt B, Bongiorno MG. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) Registry Sub-Analysis. **Europace** 2019;**21**:645-654.
57. Maggioni AP, López-Sendón J, Nielsen OW, Hallén J, Aalamian-Mattheis M, Wang Y, Ertl G. Efficacy and safety of serelaxin when added to the standard of care in patients with acute heart failure: Results from a PROBE study, RELAX-AHF-EU. **Eur J Heart Fail** 2019;**21**:322-333.

Year 2018

1. Zucchelli G, Di Cori A, Segreti L, Laroche C, Blomstrom-Lundqvist C, Kutarski A, Regoli F, Butter C, Defaye P, Pasquié JL, Auricchio A, Maggioni AP, Bongiorno MG. Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. **Europace**. 2018 Dec 27. doi: [10.1093/europace/euy300](https://doi.org/10.1093/europace/euy300). [Epub ahead of print]
2. Canepa M, Ameri P, Lucci D, Nicolosi GL, Marchioli R, Porcu M, Tognoni G, Franzosi MG, Latini R, Maseri A, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Modes of death and prognostic outliers in chronic heart failure. **Am Heart J** 2018;208:100-109.
3. Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. **J Diabetes Res**. 2018 Dec 16;2018:1631263
4. Gulizia MM, Maggioni AP. Quando un approccio puramente osservazionale non produce evidenze affidabili. **G Ital Cardiol** 2018;19:727-728
5. Maggioni AP. Audits of clinical practice should be encouraged. Use of loop diuretics in patients without a diagnosis of heart failure should be discouraged. **Eur J Prev Cardiol** 2019;26:289-290.
6. Cimminiello C, Dondi L, Pedrini A, Ronconi G, Calabria S, Piccini C, Friz HP, Martini N, Maggioni AP. Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting. **Eur J Prev Cardiol**. 2019 May;26(8):836-846.
7. Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. **Eur J Heart Fail** 2018;20:1760-1763.
8. Maggioni AP, Chioncel O. Definition, epidemiology, and burden of disease: HFrEF. In: A. John Camm, Thomas F. Luscher, Gerald Maurer, and Patrick W. Serruys: ESC CardioMed (3 ed.), ed. 3rd ed. Oxford Medicine Online 2018. DOI: [10.1093/med/9780198784906.001.0001](https://doi.org/10.1093/med/9780198784906.001.0001)
9. Pfeffer MA, Maggioni AP. Judgement over an arbitrary line. **Eur Heart J** 2018;39:4266-4268.
10. Zafir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Seferovic PM, Maggioni AP, De Mora Martin M, Polonski L, Silva-Cardoso J, Amir O; ESC-HFA HF Long-Term Registry Investigators. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. **Eur Heart J** 2018;39:4277-4284.
11. Ozierański K, Kaplon-Cieślicka A, Balsam P, Tymiąska A, Wancerz A, Peller M, Marchel M, Crespo-Leiro MG, Maggioni AP, Drożdż J, Filipiak KJ, Opolski G. Do Effect of β -blockers on 1-year survival and hospitalizations in patients with heart failure and atrial fibrillation: results from ESC-HF Pilot and ESC-HF Long-Term Registry. **Pol Arch Intern Med** 2018;128:649-657.
12. Glover BM, Hong KL, Dages N, Arbelo E, Laroche C, Riahi S, Bertini M, Mikhaylov EN, Galvin J, Kiliszek M, Pokushalov E, Kautzner J, Calvo N, Blomström-Lundqvist C, Brugada J; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. **Heart** 2019;105:244-250.
13. Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felicio JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Ohman P, Pagidipatin NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF, on behalf of the EXSCEL Study Group. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. **J Am Heart Assoc**. 2018 Oct 2;7(19):e009304. doi: [10.1161/JAHA.118.009304](https://doi.org/10.1161/JAHA.118.009304).
14. Maggioni AP, Dondi L, Pedrini A, Ronconi G, Calabria S, Cimminiello C, Martini N. The use of antiplatelet agents after an Acute Coronary Syndrome in a large community Italian setting of more than 12 million subjects. **Eur Heart J Acute Cardiovasc Care**. 2018 Sep 13;2048872618801252. doi: [10.1177/2048872618801252](https://doi.org/10.1177/2048872618801252). [Epub ahead of print]
15. Balsam P, Peller M, Borodzicz S, Kaplon-Cieślicka A, Ozierański K, Tymiąska A, Marchel M, Crespo-Leiro MG, Maggioni AP, Drożdż J, Grabowski M, Filipiak KJ, Opolski G. In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. **Cardiol J**. 2018 Aug 29. doi: [10.5603/CJ.a2018.0094](https://doi.org/10.5603/CJ.a2018.0094). [Epub ahead of print]
16. Orso F, Maggioni AP. The new definition of advanced heart failure. **Dialogues Cardiovasc Med** 2018;23 (2): 77-80
17. Giorgi-Pierfranceschi M, Artom N, Di Pasquale G, Squizzato A, Pellegrinet M, Romano G, Tana M, Mathieu G, Maggioni AP, Fontanella A, Campanini M, Mazzone A, Gussoni G, Dentali F. Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation. **Eur J Prev Cardiol** 2019;26:660-663.
18. Campodonico J, Piepoli M, Clemenza F, Bonomi A, Paolillo S, Salvioni E, Corrà U, Binno S, Veglia F, Lagioia R, Sinagra G, Cattadori G, Scardovi AB, Metra M, Senni M, Scrutinio D, Raimondo R, Emdin M, Magri D, Parati G, Re F, Cicoira M, Minà C, Limongelli G, Correale M, Frigerio M, Bussotti M, Perna E, Battaia E, Guazzi M, Badagliacca R, Di Lenarda A, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Lombardi C, Filardi PP, Agostoni P; MECKI Score Research Group. Dose-dependent efficacy of β -blocker in patients with chronic heart failure and atrial fibrillation. **Int J Cardiol** 2018; 273: 141-146.
19. Polovina M, Hindricks G, Maggioni A, Piepoli M, Vardas P, Ašanin M, Đikić D, Đurčić N, Milinković I, Seferovic PM. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. **Eur Heart J** 2018;39:4030-4039.

20. Marco Canepa, Luigi Tavazzi, Aldo P. Maggioni on behalf of the ESC HF Long Term Registry Investigators. Reply: The Barcelona Bio-HF Calculator: A contemporary web-based heart failure risk score. **J Am Coll Cardiol Heart Failure** 2018; 6: 810-811.
21. Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Störk S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S. Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. **Int J Stroke** 2019;14:270-281
22. Gulizia MM, Cemin R, Colivicchi F, De Luca L, Di Lenarda A, Boriani G, Di Pasquale G, Nardi F, Scherillo M, Lucci D, Fabbri G, Maggioni AP; BLITZ-AF Investigators. Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. **Europace** 2019;21:230-238.
23. Boriani G, Proietti M, Laroche C, Diemberger I, Popescu MI, Riahi S, Shantsila A, Dan GA, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Pilot General Registry Investigators. Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. **Int J Cardiol** 2018;271:68-74.
24. Pries AR, Naoum A, Habazettl H, Dunkel M, Preissner R, Coats CJ, Tornada A, Orso F, Van de Werf F, Wood DA; CardioScape steering committee, Van de Werf F, Wood DA, O'Kelly S, Craven J, Coats A, Sipido K, De Backer D, Wallentin L, Hasenfuss G, Della Sala L, Leggeri I; CardioScape scientific committee, Wood DA, Van de Werf F, Jaarsma T, Elliott P, Pries AR, Madonna R, Kjeldsen K, Maggioni AP, Franco OH, Hills S, Pugliese F, De Bacquer D. CardioScape mapping the cardiovascular funding landscape in Europe. **Eur Heart J** 2018;39(25):2423-2430. [scientific committee]
25. Chioncel O, Collins SP, Ambrosy AP, Pang PS, Antohi EL, Iliescu VA, Maggioni AP, Butler J, Mebazaa A. Improving Postdischarge Outcomes in Acute Heart Failure. **Am J Ther** 2018;25(4):e475-e486.
26. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverria Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. **Circ Heart Fail.** 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.
27. Vaccaro O, Riccardi G, Maggioni AP. Risk of heart failure in diabetic patients receiving sulfonylureas. **Eur J Heart Fail** 2018;20:1371-1372.
28. Maggioni AP. Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means. **Eur J Heart Fail** 2018;20:1360-1362.
29. Calabria S, Forcesi E, Dondi L, Pedrini A, Maggioni AP, Martini N. Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran. **Cardiovasc Drugs Ther** 2018;32:281-286.
30. Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group; Faculty for approval of the Consensus Document. Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. **Eur Heart J Suppl** 2018;20(Suppl F):F1-F74.
31. Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, Scotto Di Uccio F, Urbinati S, Varbella F, Zito GB, De Luca L. [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease]. **G Ital Cardiol (Rome)** 2018;19:263-331.
32. Canepa M, Fonseca C, Chioncel O, Laroche C, Crespo-Leiro MG, Coats AJS, Mebazaa A, Piepoli MF, Tavazzi L, Maggioni AP; ESC HF Long Term Registry Investigators. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. **JACC Heart Fail** 2018;6:452-462.
33. Proietti M, Laroche C, Nieuwlaat R, Crijns HJGM, Maggioni AP, Lane DA, Boriani G, Lip GYH; EORP-AF General Pilot Registry; Euro Heart Survey on AF Investigators. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. **Eur J Intern Med** 2018;55:28-34.
34. Fumagalli S, Said SAM, Laroche C, Gabbai D, Marchionni N, Boriani G, Maggioni AP, Popescu MI, Rasmussen LH, Crijns HJGM, Lip GYH; EORP-AF Investigators. Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). **JACC Clin Electrophysiol.** 2015 Aug;1(4):326-334.
35. Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, Calabria S, Scaturro G, Mantovani A, Zoppini G, Turcato E, Maggioni AP, Arcaro G, Targher G. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. **Int J Cardiol** 2018; 265:162-168

36. Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghide M, Zannad F. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). **Am J Cardiol** 2018;**122**:255-260.
37. Maggioni AP, Tavazzi L. CRT in clinical practice: some interesting news but a methodological path forward is needed. **Eur J Heart Fail** 2018;**20**:1052-1054.
38. Moccetti T, Maseri A, Maggioni AP. Lugano perspectives: final considerations. **Eur Heart J Suppl** 2018; **20 (suppl C)**: C25-C26.
39. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM; ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. **Eur J Cancer** 2018;**94**:126-137.
40. Maggioni AP, Perrone Filardi P. Lo studio REVEAL. **G Ital Cardiol** 2018;**19(2)**:71-76
41. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrianou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. **Eur J Heart Fail** 2018;**20**:853-872.
42. Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga ŞR, Maggioni AP, Paizis G, Tomic R, Catapano AL. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. **Atherosclerosis** 2018;**271**:120-127.
43. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. **Eur J Heart Fail** 2018;**20**:888-895.
44. Zeymer U, Ludman P, Danchin N, Kala P, Maggioni AP, Weidinger F. Background and design of the ACCA-EAPCI registry on ST-segment elevation myocardial infarction of the European Society of Cardiology. **Eur Heart J Acute Cardiovasc Care** 2019;**8**:63-67.
45. Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic Impact of Elevated Serum Uric Acid Levels on Long-Term Outcomes in Patients with Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. **Metabolism** 2018; **83**:205-215.
46. Migaj J, Kaluźna-Oleksy M, Nessler J, Opolski G, Crespo-Leiro M, Maggioni AP, Grajek S, Ponikowski P, Drożdż J, Straburzyńska-Migaj E. Digoxin is associated with increased risk of death in heart failure patients treated with beta-blockers. Results from Polish part of ESC HF Long-Term Registry. **Kardiologia** 2018;**76**:1064-1072.
47. Akiyama E, Van Aelst LNL, Arrigo M, Lassus J, Miró Ó, Celutkienė J, Choi DJ, Cohen-Solal A, Ishihara S, Kajimoto K, Laribi S, Maggioni AP, Motiejunaite J, Mueller C, Parenica J, Park JJ, Sato N, Spinar J, Zhang J, Zhang Y, Kimura K, Tamura K, Gayat E, Mebazaa A; GREAT (Global Research on Acute Conditions Team) Network. East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. **Eur J Heart Fail** 2018;**20**:1071-1075.
48. Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, Tendera M, Maupain C, Laroche C, Rubis P, Jurcut R, Calò L, Heliö TM, Sinagra G, Zdravkovic M, Kavaliuniene A, Felix SB, Grzybowski J, Losi MA, Asselbergs FW, García-Pinilla JM, Salazar-Mendiguchia J, Mizia-Stec K, Maggioni AP; EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. **Eur Heart J** 2018;**39**:1784-1793.
49. Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, van Thiel GJM, Cronin M, Brobert G, Vardas P, Anker SD, Grobbee DE, Denaxas S on behalf of the Innovative Medicines Initiative 2nd programme, Big Data for Better Outcomes, BigData@Heart Consortium of 20 academic and industry partners including ESC. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. **Eur Heart J** 2018;**39**:1481-1495.
50. Dan GA, Badila E, Weiss E, Laroche C, Boriani G, Dan A, Tavazzi L, Maggioni AP, Crijs HJ, Popescu R, Blommaert D, Streb W, Lip GYH on behalf of EORP-AF General Pilot Registry Investigators. Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. **Int J Cardiol** 2018;**254**:136-141.
51. Boriani G, Laroche C, Diemberger I, Fantecchi E, Meeder J, Kurpesa M, Baluta MM, Proietti M, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF General Pilot Registry Investigators. Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. **J Cardiovasc Electrophysiol** 2018;**29**:566-572.
52. Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP on behalf of the ESC-CICD Pilot Registry Investigators. The chronic ischaemic cardiovascular disease ESC Pilot Registry: results of the six-month follow-up. **Eur J Prev Cardiol** 2018;**25**:377-387.
53. Fonseca C, Maggioni AP, Marques F, Araújo I, Brás D, Langdon RB, Lombardi C, Bettencourt P. *Erratum to "A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure" [Int. J. Cardiol. 250 (2018) 215-222].* **Int J Cardiol** 2018;**254**:368-371.

54. Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N, Boriani G, Maggioni AP, Musialik-Lydkka A, Sokal A, Petersen J, Crijns HJGM, Lip GYH; EORP-AF General Pilot Registry Investigators. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. **Eur Heart J Cardiovasc Pharmacother** 2018;**4**:172-179.

Anno 2017

1. Maggioni AP, Orso F, Calabria S, Rossi E, Martini N integrantes del observatorio ARNO. Insuficiencia cardiaca en el mundo real. Un punto de vista italiano. **Rev Urug Cardiol** 2017; **32**: 321-329 [non indicizzata su PubMed, fuori dal conteggio IF]
2. De Backer GG, Maggioni AP. Foreword by the Guest Editors of the new section of the IJC, "Migration and cardiovascular disease". **Int J Cardiol.** 2017 Dec 14. pii: S0167-5273(17)36795-5. doi: 10.1016/j.ijcard.2017.12.017. [Epub ahead of print] No abstract available.
3. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR, for the EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. **Lancet Diabetes Endocrinol** 2017 Dec 5. pii: S2213-8587(17)30412-6. doi: 10.1016/S2213-8587(17)30412-6. [Epub ahead of print]
4. Wessler BS, Ruthazer R, Udelson JE, Gheorghiade M, Zannad F, Maggioni A, Konstam MA, Kent DM. Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. **J Am Heart Assoc** 2017; **6**(11). pii: e006121. doi: 10.1161/JAHA.117.006121.
5. Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow GC, Solomon SD, Lewis EF, Greene SJ, Maggioni AP, Böhm M, Zannad F, Butler J, Gheorghiade M. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. **Eur J Heart Fail.** 2017 Nov 16. doi: 10.1002/ehf.973. [Epub ahead of print]
6. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogossova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. **Lancet** 2017 Published Online November 10, 2017 [http://dx.doi.org/10.1016/S0140-6736\(17\)32409-1](http://dx.doi.org/10.1016/S0140-6736(17)32409-1)
7. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanan F, Metsarinn K, O'Donnell M, Dans A, Ha JW, Parkhomenko AN, Ryden L, Avezum A, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusuf K, Guzik TJ, Bhatt D, Branch KRH, Berkowitz S, Anand S, Fox K, Yusuf S on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial. **Lancet** 2017 Published Online November 10, 2017 [http://dx.doi.org/10.1016/S0140-6736\(17\)32458-3](http://dx.doi.org/10.1016/S0140-6736(17)32458-3)
8. A. Maggioni. Capitolo 4. Aspetti metodologici delle sperimentazioni cliniche. In: I quaderni di medicina. Il sole 24 ore Sanità. Dall'istologia al target. Il futuro della precision medicine. Allegato n. 38 del 24 ottobre 2017.
9. van Hagen IM, Baart S, Fong Soe Khioe R, Sliwa-Hahnle K, Taha N, Lelonek M, Tavazzi L, Maggioni AP, Johnson MR, Maniadakis N, Fordham R, Hall R, Roos-Hesselink JW; ROPAC investigators. Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. **Heart.** 2017 Nov 1. pii: heartjnl-2017-311910. doi: 10.1136/heartjnl-2017-311910. [Epub ahead of print]
10. Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ, Ishihara S, AlHabib KF, Maggioni A, Miró O, Sato N, Cohen-Solal A, Fairman E, Lassus J, Harjola VP, Mueller C, Peacock FW, Choi DJ, Plaisance P, Spinar J, Kosiborod M, Mebazaa A, Gayat E; GREAT (Global Research on Acute Conditions Team) Network and INI-CRCT (Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists) network. Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. **Clin Res Cardiol.** 2017 Oct 28. doi: 10.1007/s00392-017-1173-3. [Epub ahead of print]
11. Fonseca C, Maggioni AP, Marques F, Araujo I, Bras D, Langdon RB, Lombardi C, Bettencourt P, A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. **Int J Cardiol** 2018;**250**:215-222.
12. Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. **Eur J Heart Fail.** 2017 Oct 17. doi: 10.1002/ehf.1019. [Epub ahead of print]
13. Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. **Circulation** 2017;**136**:1560-1562.
14. Iannazzo S, Mannucci E, Reifsnider O, Maggioni AP. Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. **Farmeconomia. Health economics and therapeutic pathways** 2017; **18**(1): 43-53
15. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Diemberger I, Tavazzi L, Maggioni AP, Lip GYH on behalf of the EORP-AF Long-Term General Registry Investigators. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. **Europace.** 2017 Sep 14. doi: 10.1093/europace/eux301. [Epub ahead of print]
16. Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP, Chioncel O, Akiyama E, Harjola VP, Seferovic P, Laroche C, Julve MS, Roig E, Ruschitzka F, Filippatos G; ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. **Eur J Heart Fail.** 2017 Oct 8. doi: 10.1002/ehf.991. [Epub ahead of print]

17. Tymińska A, Balsam P, Ozierański K, Peller M, Kaplon-Cieślicka A, Wancerz A, Galas M, Marchel M, Crespo-Leiro MG, Maggioni AP, Drożdż J, Grabowski M, Filipiak KJ, Opolski G. Heart failure patients with a previous coronary revascularization: results from the ESC-HF Registry. **Kardiol Pol.** 2017 Oct 5. doi: 10.5603/KP.a2017.0181. [Epub ahead of print]
18. Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. **Eur J Heart Fail.** 2017 Sep 27. doi: 10.1002/ehf.988. [Epub ahead of print]
19. Canepa M, Straburzynska-Migaj E, Drozd J, Fernandez-Vivancos C, Garcia Pinilla JM, Nyolczas N, Temporelli PL, Mebazaa A, Lainscak M, Laroche C, Maggioni AP, Piepoli MF, Coats AJS, Ferrari R, Tavazzi L on behalf of the ESC-HFA Heart Failure Long-Term Registry Investigators. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. **Eur J Heart Fail.** 2017 Sep 26. doi: 10.1002/ehf.964. [Epub ahead of print]
20. Iannazzo S, Maggioni AP, Mannucci E. Analisi di impatto sul budget di empagliflozin nel trattamento dei pazienti con diabete di tipo 2 e malattia cardiovascolare accertata. **Glob Reg Health Technol Assess** 2017; 4:e122-e132.
21. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinedione or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; under the mandate of the Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. **Lancet Diabetes Endocrinol** 2017;5(11):887-897.
22. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. **N Engl J Med** 2017;377:1228-1239.
23. Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, Manolis AJ, Marzilli M, Rosano GMC, Lopez-Sendon JL. Expert consensus document: A 'diamond' approach to personalized treatment of angina. **Nat Rev Cardiol.** 2017 Sep 7. doi: 10.1038/nrcardio.2017.131. [Epub ahead of print] Review.
24. Proietti M, Laroche C, Nyvad O, Haberk M, Vassilikos VP, Maggioni AP, Boriani G, Lip GYH; EORP-AF Pilot Investigators. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. **Int J Cardiol** 2017; 248:166-172.
25. Maggioni AP. ESC Registry Results. **Dial Cardio Med** 2017;22 (3): 37-38
26. Clemenza F, Masson S, Conaldi PG, Di Carlo D, Boccanelli A, Mureddu GF, Gonzini L, Lucci D, Maggioni AP, Di Lenarda A, Nicolis EB, Vanasia M, Latini R on behalf of AREA IN-CHF Investigators. Galectin-3 and the mineralocorticoid receptor antagonist canrenone in mild heart failure. **Circ J** 2017; 81:1543-1546.
27. Gayat E, Arrigo M, Littnerova S, Sato N, Parenica J, Ishihara S, Spinar J, Müller C, Harjola VP, Lassus J, Miró Ò, Maggioni AP, AlHabib KF, Choi DJ, Park JJ, Zhang Y, Zhang J, Januzzi JL Jr, Kajimoto K, Cohen-Solal A, Mebazaa A; GREAT Network. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. **Eur J Heart Fail** 2018;20:345-354.
28. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, Trochu JN, Butler J. Heart failure with reduced ejection fraction. **Nat Rev Dis Primers** 2017;3:17058.
29. HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. **N Engl J Med** 2017; 377:1217-1227.
30. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar A, Fox KAA, Parkhomenko AN, Ertl H, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusuf K, Steg PG, Metsarinne KP, Cook Bruns N, Chen E, Shestakovska O, Leong D, Yusuf S for the COMPASS Investigators. Rivaroxaban with and without aspirin in stable cardiovascular disease. **N Engl J Med** 2017; 377:1319-1330.
31. Maggioni AP. (2017). β -blockers. In β -blockers and ACE inhibitors at the heart of cardiovascular disease (18-31). Suresnes Cedex, France: Servier.
32. Gulizia MM, Colivicchi F, Ricciardi G, Giampaoli S, Maggioni AP, Aversa M, Graziani MS, Ceriotti F, Mugelli A, Rossi F, Medea G, Parretti D, Abrignani MG, Arca M, Perrone Filardi P, Perticone F, Catapano A, Griffo R, Nardi F, Riccio C, Di Lenarda A, Scherillo M, Musacchio N, Panno AV, Zito GB, Campanini M, Bolognese L, Faggiano PM, Musumeci G, Pusineri E, Ciaccio M, Bonora E, Cantelli Forti G, Ruggieri MP, Cricelli C, Romeo F, Ferrari R, Maseri A. ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. **Eur Heart J Suppl** 2017;19(Suppl D):D3-D54.

33. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Störk S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogossova N, Dans AL, Lanus F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. **Can J Cardiol** 2017;**33**:1027-1035.
34. Dauriz M, Targher G, Temporelli P, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Tavazzi L, Maggioni AP on behalf of the GISSI-HF Investigators. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients with Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF Trial. **J Am Heart Assoc** 2017;**6**: e005156. DOI: 10.1161/JAHA.116.005156
35. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. Declining Risk of Sudden Death in Heart Failure. **N Engl J Med** 2017;**377**:41-51.
36. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. Rationale and Design of the PARAGON-HF Trial. **JACC Heart Fail** 2017; **5**:471-482
37. Maggioni AP. Uncovering difference: a glimpse at patients with heart failure in low-income and middle-income countries. **Lancet Glob Health** 2017; **5**: e634-5
38. Filippatos G, Maggioni AP, Lam CSP, Pieske-Kraigher E, Butler J, Spertus J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Bamber L, Gheorghiu M, Pieske B. Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. **Eur J Heart Fail** 2017;**19**:782-791
39. Ter Maaten JM, Maggioni AP, Latini R, Masson S, Tognoni G, Tavazzi L, Signorini S, Voors AA, Damman K. Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF. **Am Heart J** 2017;**188**:189-195.
40. Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. **J Am Heart Assoc** 2017;**6**(6). pii: e004743.
41. [SOLO PER BILANCIO SOCIALE – CENSIMENTO 2016]
42. Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. **J Am Coll Cardiol** 2017;**69**:2606-2618.
43. Pries AR, Naoum A, Habazettl H, Dunkel M, Preissner R, Coats CJ, Tornada A, Orso F, Van de Werf F, Wood DA; CardioScape steering committee: (Frans Van de Werf, David A. Wood, Sophie O'Kelly, James Craven, Andrew Coats, Karin Sipido, Dirk De Backer, Lars Wallentin, Gerd Hasenfuss, Luigi della Sala, Ilaria Leggeri); CardioScape scientific committee: (David A. Wood, Frans Van de Werf, Tiny Jaarsma, Perry Elliott, Axel Radlach Pries, Rosalinda Madonna, Keld Kjeldsen, Aldo P. Maggioni, Oscar H. Franco, Sarah Hills, Francesca Pugliese, Dirk De Bacquer). CardioScape mapping the cardiovascular funding landscape in Europe. **Eur Heart J.** 2017 Apr **25**. doi: 10.1093/eurheartj/ehx106. [Epub ahead of print]
44. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Fernandez SL, Miani D, Filippatos G, Maggioni AP; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. **Eur J Heart Fail** 2017;**19**:1242-1254.
45. Landray MJ, Reveal Collaborative Group; L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committee). Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. **Am Heart J** 2017;**187**:182-190.
46. Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). **Am Heart J** 2017;**187**:1-9.
47. Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. **Heart** 2017;**103**:1156-1162.
48. Tymińska A, Kapłon-Cieślicka A, Ozierański K, Peller M, Balsam P, Marchel M, Crespo-Leiro MG, Maggioni AP, Jankowska EA, Drożdż J, Filipiak KJ, Opolski G. Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries). **Am J Cardiol** 2017;**119**:2021-2029.
49. Packer M, O'Connor C, McMurray JJ, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J; TRUE-AHF Investigators. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. **N Engl J Med** 2017;**376**:1956-1964.
50. Proietti R, Russo V, Wu MA, Maggioni AP, Marfella R. Diabete mellito e fibrillazione atriale: evidenze di un'associazione fisiopatologica e clinico-epidemiologica che prescinde dal rischio tromboembolico. **G Ital Cardiol (Rome)** 2017;**18**(3):199-207.

51. Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E. Mechanisms linking empagliflozin to cardiovascular and renal protection. **Int J Cardiol** 2017;**241:450-456**.
52. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. **Eur J Heart Fail** 2017;**19:1574-1585**.
53. Bongioni MG, Kennergren C, Butter C, Deharo JC, Kutarski A, Rinaldi CA, Romano SL, Maggioni AP, Andarala M, Auricchio A, Kuck KH, Blomstrom-Lundqvist C on behalf of ELECTRA Investigators. The European Lead Extraction CONTRolled (ELECTRA) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. **Eur Heart J** 2017;**38(40):2995-3005**.
54. Maggioni AP. The Euroobservational research programme experience. **Dialogues in Cardiovascular Medicine** 2017; **22:50-52**.
55. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghide M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. **Eur Heart J** 2017;**38:1119-1127**.
56. Maggioni AP, Calabria S, Rossi E, Martini N. Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. **Int J Cardiol** 2017;**246:62-67**.
57. Landray MJ, Bax JJ, Alliot L, Buyse M, Cohen A, Collins R, Hindricks G, James SK, Lane S, Maggioni AP, Meeker-O'Connell A, Olsson G, Pocock SJ, Rawlins M, Sellors J, Shinagawa K, Sipido KR, Smeeth L, Stephens R, Stewart MW, Gattis Stough W, Sweeney F, Van de Werf F, Woods K, Casadei B. Improving public health by improving clinical trials guidelines and their application. **Eur Heart J** 2017;**38:1632-1637**.
58. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Boccocizumab in High-Risk Patients. **N Engl J Med** 2017;**376:1527-1539**. [Steering Committee member]
59. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Boccocizumab. **N Engl J Med** 2017;**376:1517-1526**. [Steering Committee member]
60. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van der Meer P, Roos-Hesselink JW, Seferovic P, van Spandonck-Zwarts K, Mbakwem A, Böhm M, Mouquet F, Pieske B, Hall R, Ponikowski P, Bauersachs J. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. **Eur J Heart Fail** 2017;**19:1131-1141**.
61. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA Heart Failure Long-Term Registry. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. **Diabetes Care** 2017;**40:671-678**.
62. Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L, Crijs HJ, Tavazzi L, Maggioni AP, Lip GY. Corrigendum: Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. **Sci Rep** 2017; **7:42379**.
63. Zeymer U, Ludman P, Danchin N, Kala P, Ferrari R, Maggioni AP, Weidinger F. The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction. **Eur Heart J** 2017;**38:138-139**.
64. Arbelo E, Brugada J, Lundqvist CB, Laroche C, Kautzner J, Pokushalov E, Raatikainen P, Efremidis M, Hindricks G, Barrera A, Maggioni A, Tavazzi L, Dagres N; on the behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. **Eur Heart J** 2017;**38:1303-1316**.
65. Maggioni AP, Ruschitzka F. The year in cardiology 2016: heart failure. **Eur Heart J** 2017;**38:705-711**
66. Maggioni AP, Caterson ID, Urso R, Coutinho W, Finer N, Van Gaal L, Legler UF, Sharma AM, Seimon RV, Sweeting A, Torp-Pedersen C, James WP. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. **J Cardiovasc Med (Hagerstown)** 2017;**18:144-151**.
67. Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, Park JJ, Alhabib KF, Sato N, Miro O, Maggioni AP, Zhang Y, Spinar J, Cohen-Solal A, Iwashyna TJ, Mebazaa A; GREAT Network. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. **Eur J Heart Fail** 2017; **19: 201-208**.
68. Coiro S, Girerd N, Rossignol P, Ferreira JP, Maggioni A, Pitt B, Tritto I, Ambrosio G, Dickstein K, Zannad F. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. **Eur J Heart Fail** 2017; **19:271-279**.
69. Damman K, Masson S, Lucci D, Gorini M, Urso R, Maggioni AP, Tavazzi L, Tarantini L, Tognoni G, Voors A, Latini R. Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure. **J Cardiac Fail** 2017;**23:2-9**.